An estimated 9 million Americans are taking Ozempic and other GLP-1 medications proven to suppress appetite and change how the body processes insulin. Evidence showing a 30% reduction in the consumption of sweet bakery goods, and 10% - 20% fewer calories consumed by users overall, is catching the attention of the global milling industry, particularly soft wheat millers.